Jump to Main Content
- Chen, Lei, et al. Show all 7 Authors
- Biochemical and biophysical research communications 2013 v.430 pp. 827-832
- cardiomyocytes; cardiomyopathy; cell viability; heart; heart failure; hypoxia; ischemia; phosphotransferases (kinases); vascular endothelial growth factor A
- ... HDAC inhibitors are under clinical development for the treatment of hypertrophic cardiomyopathy and heart failure although the mechanisms of protection are incompletely understood. Micro-RNA 126, an endothelium-specific miR has been assigned essential developmental roles in the heart by activating survival kinases ERK1/2 and Akt and increasing pro-angiogenic signaling. Here we provide the first ev ...
- PubMed Central: